WillItSurvive
Medical technology and health companies · Japan

MICIN

micin.jp ↗

MICIN runs curon, a Japanese telemedicine app, and MiROHA, a clinical-trial software platform.

Losing its protection
Assessed 30 July 2026 · Evidence as of 30 July 2026
The structural protection is eroding.
On the recordSince 30 July 2026 · Checkable from mid-2027 · Every call on the record Checkpoint: 12-month window (per MICIN's own trigger) to ship a customer-facing AI feature and close the gap to Medley
The call

MICIN holds a defensible clinical-trial data business while its more visible telemedicine app faces a bigger, AI-shipping rival with no confirmed new funding since 2018.

MICIN runs Curon, an online doctor-visit app in Japan, and MiROHA, a platform that helps run clinical trials and medical studies. Curon faces serious pressure from Medley, a publicly-traded competitor that just added AI tools to help doctors write faster clinical notes, a feature Curon has not yet built. Medley also has backing from NTT Docomo, Japan's largest phone company, giving it reach and resources MICIN does not. The real question is whether MICIN can prove that its clinical trial platform MiROHA is the real growth engine, or whether the company stays stuck trying to compete in consumer telemedicine where bigger players are moving faster with AI and AI-powered charting.

Why
01
AI pressure: Medley Inc.'s CLINICS platform (AI-assist clinical documentation). Medley shipped an AI charting feature in December 2025 that curon has not matched, closing the gap on clinic-facing workflow. Could AI do the core job? Only partly.
02
Bigger players: Medley, Inc. (Tokyo Stock Exchange-listed, co-operates with NTT Docomo) and M3, Inc.. Medley and M3 combine bigger distribution, listed-company capital, and live AI features against curon's scheduling and payment workflow. Could a giant copy it? Yes, easily.
03
What protects it. MiROHA's regulated pharma trial data and clinic integrations sit outside Medley's reach and are hard to copy quickly.
What would change this call
MICIN ships a customer-facing AI feature (scribe, triage, or documentation) within 12 months. Shows MICIN can close the AI gap instead of ceding curon share to Medley/M3.
MICIN announces a new priced funding round or discloses confirmed cumulative funding total. Clarifies runway and resolves the Caplight vs CBInsights funding discrepancy.
MICIN publicly explains the 2026 rename from 'Online Medical' to 'Medical Experience'. Would confirm whether MICIN is repositioning away from curon toward MiROHA DCT.
Key numbers
  • curon used by 6,000+ medical institutions (2024-09-12)
  • curon charges patients ¥330 per consultation, free to clinics (2024-09-12)
  • Series A raised $9.9M led by Mitsubishi Corp. (2018-04-30)
Named risks
  • No MICIN customer-facing AI feature shipped as of mid-2026 while Medley already launched one in Dec 2025. Severity: high
  • Core curon booking/questionnaire/payment workflow is structurally commoditizable by generic AI and video tools. Severity: high
  • Conflicting funding totals from aggregators ($85.9M vs $36.82M) leave true cumulative funding and runway unconfirmed. Severity: medium
  • Headcount appears stagnant around 120-130 from 2021 through 2024 with no confirmed newer figure. Severity: medium
  • 2026 rename of business line from Online Medical to Medical Experience signals unresolved internal repositioning. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Medley Inc.losing toMedley, TSE-listed and NTT Docomo-backed since Dec 2021, shipped AI Assist charting on CLINICS Dec 4 2025; MICIN has no equivalent as of mid-2026
M3 Inc.contestingM3's dominant physician portal and EMR arm now incorporates AI-assisted charting, encroaching on adjacent telemedicine and EMR territory
NTT Docomolosing toProvides Medley's CLINICS with telecom-scale distribution since Dec 2021, a scale advantage MICIN lacks
LINE HealthcarecontestingLINE Doctor leverages LINE's massive messaging user base for telemedicine distribution, competing directly with curon's reach
Questions people ask
Is MICIN profitable in 2026?
No public revenue or profit figures exist for MICIN as of July 2026. It is private with no financial disclosure. CEO Seigo Hara said in a 2024 interview curon is monetized via a 330 yen per-consultation fee charged to patients, with no clinic fee, but no profit figures were ever disclosed.
Who is MICIN's biggest competitor in telemedicine?
Medley Inc., which is Tokyo Stock Exchange listed and runs CLINICS with NTT Docomo since December 2021. Medley shipped an AI Assist charting feature on CLINICS on December 4, 2025, a customer facing AI capability MICIN's curon still lacked as of mid-2026.
Could AI replace MICIN's curon app?
Curon's booking, questionnaire, video call and payment layer is largely commoditizable by generic AI tools. Rival Medley already shipped an AI Assist documentation feature on CLINICS in December 2025, while no MICIN generative AI customer facing feature was found as of mid-2026.
Who owns MICIN?
MICIN is a private, VC-backed Japanese company founded November 26, 2015 by CEO Seigo Hara. Investors reported across rounds include Mitsubishi Corporation, World Innovation Lab, Sony Innovation Fund, Alfresa Holdings and DG Daiwa Ventures. It remained unlisted (未上場) per its own March 2026 press release.
Has MICIN had layoffs or restructuring?
No layoffs were reported, but MICIN's business line was renamed from Online Medical Business to Medical Experience Business in press boilerplate dated March 4, 2026, signaling an internal repositioning of its core telemedicine unit.
What is MiROHA and is it MICIN's strongest asset?
MiROHA is MICIN's regulated decentralized clinical trial platform, launched April 2020, used by pharma sponsors Amgen, GSK and Bristol Myers Squibb. It reached over 200 institutions and 4,000 patient cases by December 9, 2024, and is considered more defensible than the consumer curon app.
Timeline
  • 2026-03-04Nippon Life integrates curon into new medical insurance product launching April 2026
  • 2025-12-22MICIN posts year-end and New Year telemedicine access notice for curon
  • 2025-12-04Medley launches AI Assist charting feature on rival CLINICS platform
  • 2024-12-09MiROHA reaches 200-plus institutions and 4,000-plus patient cases
  • 2024-10-28Bristol Myers Squibb partners with MICIN and Okayama University Hospital on MiROHA
  • 2024-10-02Nippon Chouzai enables curon smart pass features across all its pharmacy stores
  • 2024-09-12CEO Hara describes curon's 330 yen per consultation model in TECHBLITZ interview
  • 2022-09-29MICIN launches curon Smart Pass cashless clinic payment service
  • 2021-12-07Medley begins co-operating CLINICS telemedicine app with NTT Docomo
  • 2020-04-01MICIN launches MiROHA decentralized clinical trial platform
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources